Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 18,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Healthy Male Volunteers
Interventions: IV methylnaltrexone (MNTX); Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: BIVV009 6.5 grams, BIVV009 7.5 grams; Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Interventions: ICP-248, Azacitidine; Drug
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Orange, California • New Haven, Connecticut • Tampa, Florida + 3 more

Conditions: Drug-drug Interaction
Interventions: Tucatinib, Metformin, Iohexol; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endometrial Cancer
Interventions: Hypofractionated WPRT; Radiation
Lead sponsor: Teresa Meier; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure, Congestive
Interventions: CD-NP; Drug
Lead sponsor: Nile Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 with Matrix M-2, GEN-003, Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more

Conditions: Melanoma
Interventions: Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more

Conditions: Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions: TUB-030; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Breast Cancer, Fatigue, Hypothyroidism
Interventions: physiologic testing, fatigue assessment and management, management of therapy complications; Other · Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 41
States / cities: Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more

Conditions: Leukemia, Lymphoma
Interventions: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Anaplastic Thyroid Cancer
Interventions: CS-7017, Paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 7 more

Conditions: Healthy
Interventions: K-285, Indomethacin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 3 more

Conditions: Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions: AB-201, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions: ONCOS-102, Durvalumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: San Diego, California • Miami, Florida • Buffalo, New York + 3 more

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions: Cemiplimab, Cisplatin, Docetaxel; Drug
Lead sponsor: Krzysztof Misiukiewicz; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatic Impairment
Interventions: oral dose of 200 mg pacritinib twice daily (BID); Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT); Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • New York, New York + 2 more

Conditions: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Interventions: KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Propionic Acidemia
Interventions: mRNA-3927; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 4 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
Interventions: CD19CAR/virus specific T cells, Benadryl and Tylenol; Genetic · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2031
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer

Safety and Pharmacodynamic Study of CD-NP

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT